Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 102 Issue 2, February 2022

In this issue (p 172), Innes et al present an experimental approach to simultaneously barcode and phenotype glioma initiating cells to assess their functional properties The cover shows the clonal populations that emerge during passaging of barcode-labelled cells.

Inside the USCAP Journals

Top of page ⤴

Review Article

  • Vitamin D has recently emerged as a neurosteroid and a regulator of various physiological functions. It has been widely reported to promote tumor-suppressive effects, however this proposal remains controversial. This article reviews the anti-tumoral mechanisms of vitamin D in glioblastoma, current evidence of its therapeutic application as a supplement to standard chemotherapy, and its potential applications for cancer prevention; it endeavors to offer insight into new means of overcoming chemoresistance and improving glioma patient survival.

    • Carmen Sze-Ching Lo
    • Karrie Mei-Yee Kiang
    • Gilberto Ka-Kit Leung

    Collection:

    Review Article
  • The 5th edition of WHO Classification of Tumors of the Central Nervous System adopted new molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, i.e., the CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, as independent molecular markers of the highest grade.

    • Takashi Komori

    Collection:

    Review Article
  • Cell-free DNA (cfDNA) profiling as liquid biopsy is of clinical utility in carcinomas of adult-onset. However, its application in childhood cancers, including brain tumors, has not been as extensively studied. In this article, we review the current status of applying cfDNA analysis for pediatric central nervous system neoplasms. Technical challenges, evidence for utility based on current literature, and potential future developments are discussed.

    • Anthony Pak-Yin Liu
    • Paul A. Northcott
    • Amar Gajjar

    Collection:

    Review Article
Top of page ⤴

Article

Top of page ⤴

Technical Report

Top of page ⤴

Correction

Top of page ⤴

Search

Quick links